Johnson & Johnson Cut to “Neutral” at Goldman Sachs (JNJ)

By
A A A
Share |

Healthcare giant Johnson & Johnson ( JNJ ) on Thursday caught a big downgrade from analysts at Goldman Sachs.

The firm said it lowered its rating on JNJ from "Buy" to "Neutral" with a $74 price target. That target suggests a 17% upside to the stock's Wednesday closing price of $63.13.

Goldman noted that while it still likes JNJ, two factors have made them a bit less bullish: The drugmaker's Xarelto treatment won't be nearly as successful as originally forecast, and the fact that its Medical Devices and Diagnostics segment is seeing weak utilization trends.


Johnson & Johnson shares fell $1.03, or -1.6%, in premarket trading Thursday.

The Bottom Line
Shares of Johnson & Johnson ( JNJ ) have a 3.61% dividend yield, based on last night's closing stock price of $63.13. The stock has technical support in the $58-$60 price area. If the shares can firm up, we see overhead resistance around the $66-$68 price levels.

Johnson & Johnson ( JNJ ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Created by Dividend.com


This article appears in: Investing , Stocks

Referenced Stocks: JNJ

Dividend.com

Dividend.com

More from Dividend.com:

Related Videos

Stocks

Referenced

77%

Most Active by Volume

33,974,386
  • $17.98 ▲ 0.28%
20,763,901
  • $91.29 ▲ 2.06%
19,110,793
  • $7.26 ▼ 1.22%
18,528,869
    $8.33 unch
18,014,920
  • $4.19 ▼ 1.18%
16,448,919
  • $25.83 ▼ 0.19%
14,748,190
  • $7.60 ▼ 1.43%
14,144,383
  • $112.01 ▼ 0.47%
As of 12/24/2014, 02:12 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com